Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
Boehringer Ingelheim
Baxter
Johnson and Johnson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,348,361

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,348,361 protect, and when does it expire?

Patent 7,348,361 protects CYSVIEW KIT and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 7,348,361
Title:Solution for diagnosing or treating tissue pathologies
Abstract:The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
Inventor(s): Marti; Alexandre (Geneva, CH), Lange; Norbert (Lausanne, CH), Zellweger; Matthieu (Lausanne, CH), Wagnieres; Georges (Morges, CH), Van Den Bergh; Hubert (Goumoens-la-Ville, CH), Jichlinski; Patrice (Le Mont-sur-Lausanne, CH), Kucera; Pavel (Lausanne, CH)
Assignee: Ecole Polytechnique Federale de Lausanne (Lausanne, CH)
Application Number:09/673,871
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;

Drugs Protected by US Patent 7,348,361

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes   Start Trial   Start Trial Y DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY   Start Trial
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes   Start Trial   Start Trial Y DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,348,361

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 05425Apr 22, 1998
PCT Information
PCT FiledApril 22, 1999PCT Application Number:PCT/CH99/00163
PCT Publication Date:October 28, 1999PCT Publication Number: WO99/53962

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Moodys
Harvard Business School
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.